131 related articles for article (PubMed ID: 36999405)
1. Correlation between methylation level of the
Huang X; Hao Q; Fang Q; Zhang P; Wei H; Wang Y; Wang J; Mi Y
Pharmacogenomics; 2023 Apr; 24(5):261-268. PubMed ID: 36999405
[No Abstract] [Full Text] [Related]
2. Methylation analysis of the SLC19A1 promoter region in Chinese children with acute lymphoblastic leukaemia.
Wang SM; Li M; Wu WS; Sun LL; Yan D
J Clin Pharm Ther; 2020 Aug; 45(4):646-651. PubMed ID: 32403197
[TBL] [Abstract][Full Text] [Related]
3. Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma.
Faganel Kotnik B; Grabnar I; Bohanec Grabar P; Dolžan V; Jazbec J
Eur J Clin Pharmacol; 2011 Oct; 67(10):993-1006. PubMed ID: 21509569
[TBL] [Abstract][Full Text] [Related]
4. Effects of a microRNA binding site polymorphism in SLC19A1 on methotrexate concentrations in Chinese children with acute lymphoblastic leukemia.
Wang SM; Sun LL; Zeng WX; Wu WS; Zhang GL
Med Oncol; 2014 Jul; 31(7):62. PubMed ID: 24927955
[TBL] [Abstract][Full Text] [Related]
5. MiR-595 Suppresses the Cellular Uptake and Cytotoxic Effects of Methotrexate by Targeting SLC19A1 in CEM/C1 Cells.
Wang SM; Sun LL; Wu WS; Yan D
Basic Clin Pharmacol Toxicol; 2018 Jul; 123(1):8-13. PubMed ID: 29345051
[TBL] [Abstract][Full Text] [Related]
6. MiR-pharmacogenetics of methotrexate in childhood B-cell acute lymphoblastic leukemia.
Iparraguirre L; Gutierrez-Camino A; Umerez M; Martin-Guerrero I; Astigarraga I; Navajas A; Sastre A; Garcia de Andoin N; Garcia-Orad A
Pharmacogenet Genomics; 2016 Nov; 26(11):517-525. PubMed ID: 27649261
[TBL] [Abstract][Full Text] [Related]
7. Global methylation in relation to methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia.
Oosterom N; Griffioen PH; den Hoed MAH; Pieters R; de Jonge R; Tissing WJE; van den Heuvel-Eibrink MM; Heil SG
PLoS One; 2018; 13(7):e0199574. PubMed ID: 29985926
[TBL] [Abstract][Full Text] [Related]
8. Association between reduced folate carrier G80A polymorphism and methotrexate toxicity in childhood acute lymphoblastic leukemia: a meta-analysis.
He HR; Liu P; He GH; Dong WH; Wang MY; Dong YL; Lu J
Leuk Lymphoma; 2014 Dec; 55(12):2793-800. PubMed ID: 24597986
[TBL] [Abstract][Full Text] [Related]
9. Association of GGH Promoter Methylation Levels with Methotrexate Concentrations in Chinese Children with Acute Lymphoblastic Leukemia.
Wang SM; Kong XY; Li M; Sun LL; Yan D
Pharmacotherapy; 2020 Jul; 40(7):614-622. PubMed ID: 32476160
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia.
Lopez-Lopez E; Ballesteros J; Piñan MA; Sanchez de Toledo J; Garcia de Andoin N; Garcia-Miguel P; Navajas A; Garcia-Orad A
Pharmacogenet Genomics; 2013 Feb; 23(2):53-61. PubMed ID: 23222202
[TBL] [Abstract][Full Text] [Related]
11. Can SLC19A1 80G>A polymorphisms predict risk of extremely delayed MTX excretion after high dose of methotrexate?
Rasmussen MM; Christensen RH; Gregers J; Heldrup J; Nersting J; Schmiegelow K
J Pediatr Hematol Oncol; 2013 Jul; 35(5):417-8. PubMed ID: 23669721
[No Abstract] [Full Text] [Related]
12. Effect of polymorphisms in transporter genes on dosing, efficacy and toxicity of maintenance therapy in children with acute lymphoblastic leukemia.
Gervasini G; de Murillo SG; Jiménez M; de la Maya MD; Vagace JM
Gene; 2017 Sep; 628():72-77. PubMed ID: 28710036
[TBL] [Abstract][Full Text] [Related]
13. Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies.
Suthandiram S; Gan GG; Zain SM; Bee PC; Lian LH; Chang KM; Ong TC; Mohamed Z
Pharmacogenomics; 2014 Aug; 15(11):1479-94. PubMed ID: 25303299
[TBL] [Abstract][Full Text] [Related]
14. SLC19A1 hot spot for MTX plasma concentration.
Gutierrez-Camino A; Lopez-Lopez E; Garcia-Orad A
Med Oncol; 2014 Oct; 31(10):204. PubMed ID: 25178938
[No Abstract] [Full Text] [Related]
15. Pharmacogenomic Markers of Methotrexate Response in the Consolidation Phase of Pediatric Acute Lymphoblastic Leukemia Treatment.
Kotur N; Lazic J; Ristivojevic B; Stankovic B; Gasic V; Dokmanovic L; Krstovski N; Milosevic G; Janic D; Zukic B; Pavlovic S
Genes (Basel); 2020 Apr; 11(4):. PubMed ID: 32344632
[TBL] [Abstract][Full Text] [Related]
16. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
[TBL] [Abstract][Full Text] [Related]
17. Methotrexate Disposition in Pediatric Patients with Acute Lymphoblastic Leukemia: What Have We Learnt From the Genetic Variants of Drug Transporters.
Hu YH; Zhou L; Wang SS; Jing X; Guo HL; Sun F; Zhang Y; Chen F; Xu J; Ji X
Curr Pharm Des; 2019; 25(6):627-634. PubMed ID: 30931851
[TBL] [Abstract][Full Text] [Related]
18. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.
Radtke S; Zolk O; Renner B; Paulides M; Zimmermann M; Möricke A; Stanulla M; Schrappe M; Langer T
Blood; 2013 Jun; 121(26):5145-53. PubMed ID: 23652803
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia.
Lopez-Lopez E; Martin-Guerrero I; Ballesteros J; Piñan MA; Garcia-Miguel P; Navajas A; Garcia-Orad A
Pediatr Blood Cancer; 2011 Oct; 57(4):612-9. PubMed ID: 21387541
[TBL] [Abstract][Full Text] [Related]
20. Methotrexate pharmacogenetics in Uruguayan adults with hematological malignant diseases.
Giletti A; Vital M; Lorenzo M; Cardozo P; Borelli G; Gabus R; Martínez L; Díaz L; Assar R; Rodriguez MN; Esperón P
Eur J Pharm Sci; 2017 Nov; 109():480-485. PubMed ID: 28887233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]